HemaSphere Journal

🤝Transparency notice: HemaSphere's article processing charges (APCs) will change for new manuscript submissions as of January 1, 2025. Many authors will benefit from our publisher's (@WileyOnc_Hem) extensive transformational agreement network, which could fully cover APCs. Active #EHA members will continue to be eligible for a 10% discount. Despite the adjustment, HemaSphere’s 2025 APCs remain competitively priced and will be: • Tier 1 - Articles, Review Articles, Guidelines: €2140 • Tier 2 - Perspectives, Letters: €1290 • Tier 3 - Editorials, Comments, HemaTopics, HemaPolicy: €0 #HemaSphere #OpenAccess More details here: https://bit.ly/49gBUcw

To date no AML-exclusive, non-HSPC-expressed cell-surface target molecules for AML selective immunotherapy have been identified. Time-limited combined immune-targeting of AML cells & healthy HSPCs, followed by HSCT might be a viable therapeutic approach👉

This population-based study examined COD in 20K+ CLL patients in the Netherlands between 1996 and 2020. Findings reveal CLL as the predominant COD, around 40% of relative mortality, with a declining 5-year death probability from 16.8% in 1996–2002 to 7.6% in 2010–2020. This comprehensive analysis underscores a noticeable reduction in CLL-attributed deaths and other competing causes, yet as CLL is registered as the most prevalent cause of mortality among contemporary diagnosed patients, this emphasizes the continued relevance of CLL-centric clinical strategies and research. Read about it 👉

Sci Ed Dr Charles de Bock hosts Dr Thomas Mercher & Dr Alexandre Fagnan in this episode, highlighting ETO2 activated gene transcription & how this affects erythroleukemia. The discussion traces the journey from Dr Fagnan’s PhD project (2022 #EHA Junior Grant awardee), the findings in the paper & what may lie beyond. This episode is on our website https://bit.ly/4cz0Tbr & all major podcast platforms  Listen & enjoy casual, insightful discussions about hematology research.

Reducing the overall duration of Isa infusion from 75 to 30 min with a new method, shown to be is feasible, safe, and well tolerated, facilitating IV administration in clinical practice and resulting in time savings for both patients and healthcare providers. Read about it here 👉https://bit.ly/4fdGoBY

HemaTopics are HemaSphere publications focusing on hot hematology topics including recent research developments, updates on diagnosis and treatment, policy and guidelines news, and more. This week we focus on the latest HemaTopic by Scientific Editor D Kent, which discusses cytokine signaling dynamics in light of a recent study  focusing on inhibition of IL-11.  Read about it 👉https://bit.ly/41a9NK2

Authors report the outcome of patients enrolled in the EORTC 58081 study, comparing these results, overall and by predefined subgroups, with those obtained for the PRED arm of the previous EORTC 58951 study and evaluated the prognostic importance of the MRD level at the end of induction in the EORTC 58081 study. Read more about it 👉

HemaSphere Podcast 2024 Replay! In this episode, Dr. Francesca Vinchi interviews Professor Alessandra Balduini about thrombopoiesis and highlights Dr. Vinchi's HemaTopic paper, "Targeting Bone Marrow Mechanosensation in Myelofibrosis." They explore Prof. Balduini's journey into research, her intuition that led to silk scaffolding, and her hopes on future results.  "Unraveling the Secrets of Thrombopoiesis" is available on our website https://bit.ly/3vjlUqQ and all major podcast platforms (Spotify, Apple Podcasts, etc.) and our YouTube channel, https://lnkd.in/eRviSByB . Enjoy the episode and check out the full open-access article on the HemaSphere website. Tune in for casual and insightful discussions on hematology research.

This recent study involving over 75,000 participants revealed that nearly 10% of individuals with MGUS have multiple paraproteins, with IgM being more common.  Findings indicate that different paraproteins reflect relatively independent underlying disease processes, but during the relatively short study follow-up, progression risk is similar for those with multiple and single paraproteins.  Read more about this study here 👉https://bit.ly/3OAqQxy #MGUS #paraprotein #hematology

🎧New HemaSphere Podcast Episode! This podcast episode hosted by HemaSphere Scientific Editor Dr Charles de Bock delves into the complexities of informed consent in healthcare, particularly in the context of hematology. The discussion features insights from Dr Stephen Hibbs and Dr Louise Caldwell, authors of the HemaTopics "Informed consent is almost impossible” and guest Mark Dawson, a patient family member, exploring the emotional, legal, and ethical dimensions of consent. Key themes include the variability of consent across jurisdictions, the impact of time pressures on communication, and the importance of trust in the clinician-patient relationship. The conversation also addresses the challenges posed by genetic testing and the need for ongoing discussions about consent throughout a patient's treatment journey. “Informed consent is almost impossible”, is on our website https://bit.ly/4ePvpPg and all major podcast platforms (Spotify, Apple Podcast, and more) and our YouTube channel https://bit.ly/3VdjFiB Listen and enjoy casual, insightful discussions about #hematology research. Hear the stories behind the papers. You can find the referenced article, in full and open access, on the HemaSphere website https://bit.ly/3ztaX7V